Intercept Pharmaceuticals to Host 2013 Full Year Financial Results and Business Update Conference Call on March 17

Intercept Pharmaceuticals to Host 2013 Full Year Financial Results and Business Update Conference Call on March 17  NEW YORK, March 10, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced that it will report 2013 full year financial results after the NASDAQ Market closes on Friday, March 14, 2014. Intercept management will conduct a conference call and audio webcast on Monday, March 17, 2014 at 8:30 a.m. EDT to discuss these results and provide an update on the company's business.  Date: March 17, 2014 Time: 8:30 AM ET  Listen via Internet: http://ir.interceptpharma.com/  Schedule this webcast into MS-Outlook calendar (click open when prompted): http://apps.shareholder.com/PNWOutlook/t.aspx?m=63531&k=48456EB8  Toll-free: (855) 232-3919 International: (315) 625-6894  A replay of the call will be available on Intercept's website approximately two hours after the completion of the call and will be archived for two weeks.  Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver and intestinal diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases including primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH), portal hypertension, bile acid diarrhea and primary sclerosing cholangitis (PSC). OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside of Japan and China, where it has out-licensed the product candidate to Dainippon Sumitomo Pharma (DSP). For more information about Intercept, please visit the Company's website at: www.interceptpharma.com.  CONTACT: Intercept Pharmaceuticals, Inc.          Barbara Duncan or Senthil Sundaram          646-747-1000          investors@interceptpharma.com  
Press spacebar to pause and continue. Press esc to stop.